Combination immunotherapy in chemotherapy in gastric cancer

On the basis of the results of the CheckMate 649 trial1 and the KEYNOTE-859 trial,2 the standard regimen for patients with advanced, untreated, HER2-negative gastric cancer is doublet chemotherapy combined with an immune checkpoint inhibitor. However, the prognosis for advanced gastric cancer remains poor, particularly for patients with low PD-L1 expression.